Drugs for Neglected Diseases initiative (DNDi)

🌍We are pleased to announce that the Kenya Medical Research Institute (KEMRI) has joined the Dengue Alliance, making Kenya the first African country part of this global partnership dedicated to advancing dengue treatment research. 👉 More details: dndi.org/press-releas...

At @worldhealthsummit.bsky.social in Berlin, @dndi.org, @gardp.bsky.social & MMV invited partners to explore how stronger collaboration can sustain health innovation, strengthen local capabilities and accelerate access to the treatments people need. Turning shared ambition into collective action.

A new joint perspective paper from GARDP, @dndi.org, @mmv.org and MDGH sets out 7 recommendations to strengthen the WHO functions that support needs-driven R&D and access, particularly where commercial incentives are limited. 📄 gardp.org/strengthenin...

A decade of reforms helped reduce Colombia's #Chagas disease treatment gap from 77.5% to 48.1%. This study shows that monitoring treatment access can help identify barriers and guide efforts to ensure more people receive the care they need. Link to study: doi.org/10.1590/0074...

Congratulations to our Continental Lead for Africa, Prof @eadirectordndi.bsky.social, on his induction into the US @nam.edu this weekend! He’s recognized for his work on drug-resistant food and waterborne infections and vaccine programmes in sub-Saharan Africa.

Acoziborole has shown promise as a single-dose treatment for gambiense sleeping sickness. This study in @plos.org suggests it could be equally effective against rhodesiense sleeping sickness, an important step toward eliminating the disease. journals.plos.org/plosntds/art...

✈️GHTC ED Kristie Mikus is heading to Berlin for #WHS! We look forward to engaging with you all - including at a PDP-focused event w/ @mmv.org, @popcouncil.bsky.social, IVCC, @tballiance.bsky.social, @dsw-intl.bsky.social, @path.org, & @dndi.org. See more! www.worldhealthsummit.org/sessions/4f5...

India supplies around 20% of the world’s generic medicines & is one of the largest vaccine manufacturers globally. But could it play a leading role in developing tomorrow's medicines? Read our Asia Continental Lead Sanjay Sarin's op-ed in BusinessLine: www.thehindubusinessline.com/specials/pul...

I’ll be speaking at the World Health Summit 2026 in Berlin. 📍 Workshop: Shaping the Global Health Architecture and Ending Diseases of Poverty 📅 11 October | 16:00–17:30 📌 Forum 2 #WHS2026 #GlobalHealth #Mycetoma #NTDs @dndi.org

We're proud to be recognized as a Very High Performer in the 2026 Gender & Health Index by Global Health 50/50! We remain committed to improving gender equity both inside our organization & through our work for patients affected by neglected diseases. Full report: global5050.org/accountabili...

Pleased to launch our first drug discovery partnership in Africa with KNUST. We’ll screen 100 compounds against schistosomiasis parasites, to develop the next gen of treatments while strengthening African-led drug discovery capacity. Supported by the BMFTR. www.dndi.org/press-releas...

Patricia survived cryptococcal meningitis, but still lives with its consequences: the loss of her sight. This neglected disease is preventable & treatable, yet it remains one of the leading causes of death among people living with advanced HIV. #WorldMeningitisDay youtu.be/ISfRm9rjyc0

Who gets included in clinical trials matters because the treatments we develop need to reflect the needs and realities of the people who will use them. 👉 @who.int is seeking input on improving the inclusion of underrepresented populations in clinical trials: extranet.who.int/dataformv6/i...

🌍 But #dengue is not just a challenge for Bangladesh. Climate change, rainfall, & urbanization affect where & when outbreaks occur. There's still no specific treatment for dengue. With millions at risk worldwide, developing one is an urgent global health priority. straitstimes.com/asia/south-a...

🤝 GARDP and @dndi.org are pleased to announce support from the Foundation for the Adaptation of International Geneva to strengthen collaboration, share capabilities and resources, and help both focus more on developing and ensuring access to treatments for NTDs and drug-resistant infections.

🌍 Getting ready for #WHS2026! On 11 Oct, Dr Borna Nyaoke-Anoke, our Head of Mycetoma, will speak at a session to discuss the role of product development partnerships (PDPs) in advancing health equity. 🔗 Join us: worldhealthsummit.org/sessions/4f5... #WorldHealthSummit

At #UNGA81, our Senior Policy Advocacy Manager Rachael Crockett explains why Article 9.5 of the WHO Pandemic Agreement could be a game changer for equitable access. 🔗 Read our intervention at UNGA: dndi.org/statements/2...

Cutaneous #leishmaniasis is particularly difficult to treat in Ethiopia. A trial of thermotherapy and intralesional sodium stibogluconate found low cure rates, but thermotherapy may be a pragmatic choice when access to drugs is limited. link.springer.com/article/10.1... @bmc.springernature.com

Our first panel session is on 'Delivering the #100DaysMission: Building the Enabling Ecosystem', with insights from @dndi.org, @cepi.net and @ippsecretariat.org. What are the capabilities, partnerships and investments needed to accelerate medical countermeasure readiness? #UNGA81

@covid-moonshot.bsky.social & @asapdiscovery.bsky.social researchers tell us how they developed innovative approaches to IP, enabling open science drug discovery while ensuring non-exclusive manufacturing & equitable access. 🎧 open.spotify.com/episode/5CBi... #UNGA81 #PandemicPrep #OpenScience

New report worth reading from @dndi.org "Implementing Article 9.5 of the WHO #PandemicAgreement – building on current policy and practice for publicly funded R&D" dndi.org/wp-content/u...

Join us at #UNGA81 to discuss how to better prepare for pandemics through R&D & the 100 Days Mission. The 100 Days Mission aims to ensure the development & delivery of diagnostics, therapeutics, & vaccines within 100 days of a pandemic threat being identified. 🕗 8:00–9:30 a.m. ET 🔗 dvx.cm/bgxtab

🔬 212 R&D and access partner institutions in 47 countries 🧪 41 clinical trial sites in 16 countries 🔎 To learn more about our activities: dndi.org/about/annual...

Can oxfendazole help eliminate lymphatic filariasis? This Phase IIa proof‑of‑concept trial published in @springernature.com will evaluate its safety & ability to target adult filarial worms, helping guide development of new treatments. link.springer.com/article/10.1...

Finding new treatments for #Chagas disease starts with better tools. This study developed a high‑throughput screening assay for T. cruzi & identified promising compounds that block protein synthesis, opening new avenues for drug discovery. @IJPara www.sciencedirect.com/science/arti...

As part of the 2025–26 #WithoutBordersMediaFellowship, journalist Rituparna Palit, a recipient of the MSF SouthAsia-DNDi Grant on #NTDs, explores #mycetoma in her latest feature for The Scientist: www.the-scientist.com/mycetoma-the...

For the first time, dengue mosquitoes have been found breeding in London. As our climate warms, invasive mosquitoes are increasingly being detected in new areas. But despite this growing global threat, there is still no treatment for dengue. @bbcnewsunofficial.bsky.social www.bbc.com/news/article...

📅 9 Sept | 15:00-17:00 CEST 📍 @europarl.europa.eu& online How can public investment in health R&D deliver greater public benefit? Join MPP, @dndi.org & @saludporderecho.bsky.social to explore how access planning can help make publicly funded research more accessible and affordable. 🔗 bit.ly/3VbYRdS

Our Asia Continental Lead, Sanjay Sarin, shares his perspectives with BioSpectrum Asia on the future of #NTD research in Asia, the rising burden of dengue, and the partnerships needed to accelerate the development of affordable, accessible treatments: www.biospectrumasia.com/opinion/29/2...

Join us for a discussion on the growing practice of Access Planning in R&D, examining how it can help ensure that publicly funded R&D translates into timely public health-driven innovation and accessible, affordable, and available resulting health technologies. docs.google.com/forms/d/e/1F...

Why do women remain underrepresented in clinical trials & how do we address the gaps? Join @dndi.org & IQVIA for a hybrid Media Science Café on gender-responsive R&D. 🗓️ Friday, 4th September, 2026 ⏲️ 11:00-13:00 EAT 🔗 Register here bit.ly/4cnjWIl #WomensHealth #HealthforAll

How to unlock the power of crowdsourced science to prepare for future coronavirus pandemics? Read our latest Drug Discovery Explained story on the @covid-moonshot.bsky.social and @asapdiscovery.bsky.social #openscience initiatives: 🔗 stories.dndi.org/drug-discove... #pandemicpreparedness

swissinfo.ch takes a closer look at the strategic collaboration between DNDi, @mmv.org and @gardp.bsky.social as the global health landscape changes. 🔗Read here: www.swissinfo.ch/eng/new-trea...

We are proud to contribute to a new publication in the Journal of Translational Medicine on ICH E21 - guidance to improve the inclusion of pregnant and breastfeeding individuals in clinical trials and address evidence gaps in their care. link.springer.com/epdf/10.1186...

Ten years ago, #mycetoma joined the @who.int list of neglected tropical diseases. So what has a decade of recognition made possible? And what still hasn't changed? Our new digital story brings the whole decade together. dndi.org/stories/2026... #MycetomaAt10 #BeatNTDs

When public money funds pandemic innovations, who benefits? Article 9.5 of the WHO Pandemic Agreement requires governments to develop policies on how publicly funded R&D can support equitable access to the products that result from it. Learn more ⤵️

🦟 Kenya is currently experiencing an upsurge in #dengue fever, with cases concentrated in Garissa and Wajir counties and now spreading to the coastal region. The two counties have recorded several deaths since the outbreak began a couple of months ago. There is no specific treatment for dengue.

Writer Daisy Hernández @dazeher.bsky.social joins our podcast to reflect on how her aunt’s experience with #Chagas disease exposed a wider public health failure affecting millions. We talk about the impact of NTDs, barriers to care, and the power of patient stories. open.spotify.com/episode/5COi...

A new sleeping sickness drug -acoziborole, recently got approved in the DRC. A single dose, 96% effective, developed & trial-tested by African scientists. This @nature.com op-ed argues this is a glimpse of Africa's growing leadership in medical innovation. @dndi.org 🔗 bit.ly/4giHUGN

The issue isn’t only that millions live with #Chagas disease & cutaneous #leishmaniasis. The issue is that science struggles to respond fast enough. New study shows how collaborative platforms are reshaping research: cooperation, tech transfer & shared governance. 📖 www.scielo.br/j/physis/a/N...

🌍 We’re #hiring! We are seeking an Executive Director to lead DNDi through our next phase of impact, innovation, & sustainable growth. 📌 Based in Geneva, Switzerland ✅ Full-time position – 100% 📆 Deadline: 15 September 2026 👉 Find out more and apply here: careers-dndi.icims.com/jobs/1246/ex...

Good news! @WHO recommends new treatment guidelines for #leishmaniasis. East Africa: new combo treatment is 90%+ effective, cuts injections 34→14, hospitalization 60-90→14 days. South Asia: safer PKDL options, less toxic. Read more bit.ly/4x9OYv3 #BeatNTDs @dndi.org